HKSE:06990'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2.17 Med: -1.53 Max: -0.7
Current: -0.81
During the past 3 years, the highest Earnings Yield (Joel Greenblatt) of Sichuan Kelun-Biotech Biopharmaceutical Co was -0.70%. The lowest was -2.17%. And the median was -1.53%.
HKSE:06990's Earnings Yield (Joel Greenblatt) % is ranked better than 77.88% of 1415
companies
in the Biotechnology industry
Industry Median: -15.65
vs HKSE:06990: -0.81
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Sichuan Kelun-Biotech Biopharmaceutical Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Sichuan Kelun-Biotech Biopharmaceutical Co Earnings Yield (Joel Greenblatt) % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sichuan Kelun-Biotech Biopharmaceutical Co Earnings Yield (Joel Greenblatt) % Chart
Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Earnings Yield (Joel Greenblatt) %
-
-
-2.11
Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings Yield (Joel Greenblatt) % falls into.
Sichuan Kelun-Biotech Biopharmaceutical Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Sichuan Kelun-Biotech Biopharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-273.3 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Sichuan Kelun-Biotech Biopharmaceutical Co Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06990 has been successfully added to your